Novel mutation in cytochrome B of Plasmodium falciparum in one of two atovaquone-proguanil treatment failures in travelers returning from same site in Nigeria

Open Forum Infectious Diseases

Volumn 1, Issue 2, 2014, Pages

  Plucinski, Mateusz M ^a   Huber, Curtis S ^a   Akinyi, Sheila ^a   Dalton, Willard ^b   Eschete, Mary ^b   Grady, Katharine ^a   Silva Flannery, Luciana ^a   Mathison, Blaine A ^a   Udhayakumar, Venkatachalam ^a   Arguin, Paul M ^a   Barnwell, John W ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b Terrebonne General Medical Center   (United States)

Author keywords

Dihydrofolate reductase; Drug resistance; Malaria; Malarone; Plasmodium falciparum

Indexed keywords

ATOVAQUONE; CLINDAMYCIN; CYTOCHROME B; DIHYDROFOLATE REDUCTASE; DOXYCYCLINE; PROGUANIL; QUINIDINE;

ADULT; ARTICLE; CASE REPORT; CHEMOPROPHYLAXIS; DIARRHEA; FOLLOW UP; GENE; GENETIC ANALYSIS; GENOTYPE; HUMAN; INFECTION RATE; LOSS OF APPETITE; MALARIA; MALARIA FALCIPARUM; MIDDLE AGED; MITOCHONDRIAL GENOME; NIGERIA; PARASITEMIA; PFCYTB GENE; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TREATMENT FAILURE;

EID: 84921954966     PISSN: None     EISSN: 23288957     Source Type: Journal    
DOI: 10.1093/ofid/ofu059     Document Type: Article

References (41)

1. LaRocque RC, Rao SR, Lee J, et al. Global TravEpiNet: a national consortium of clinics providing care to international travelers-analysis of demographic characteristics, travel destinations, and pretravel healthcare of high-risk US international travelers, 2009-2011. Clin Infect Dis 2012; 54:455-62.
2. Cullen KA, Arguin PM. Malaria surveillance-United States, 2011. MMWR Surveill Summ 2013; 62:1-17.
3. Bouchaud O, Mühlberger N, Parola P, et al. Therapy of uncomplicated falciparum malaria in Europe: MALTHER: a prospective observational multicentre study. Malar J 2012; 11:1-8.
4. Cordel H, Cailhol J, Matheron S, et al. Atovaquone-proguanil in the treatment of imported uncomplicated Plasmodium falciparum malaria: a prospective observational study of 553 cases. Malar J 2013; 12:399.
5. Musset L, Le Bras J, Clain J. Parallel evolution of adaptive mutations in Plasmodium falciparum mitochondrial DNA during atovaquoneproguanil treatment. Mol Biol Evol 2007; 24:1582-5.
6. Savini H, Bogreau H, Bertaux L, et al. First case of emergence of atovaquone- proguanil resistance in Plasmodium falciparum during treatment in a traveler in Comoros. Antimicrob Agents Chemother 2008; 52:2283-4.
7. Fivelman QL, Butcher GA, Adagu IS, et al. Malarone treatment failure and in vitro confirmation of resistance of Plasmodium falciparum isolate from Lagos, Nigeria. Malar J 2002; 1:1.
8. Färnert A, Lindberg J, Gil P, et al. Evidence of Plasmodium falciparum malaria resistant to atovaquone and proguanil hydrochloride: case reports. BMJ 2003; 326:628-9.
9. Schwartz E, Bujanover S, Kain KC. Genetic confirmation of atovaquone- proguanil-resistant Plasmodium falciparum malaria acquired by a nonimmune traveler to East Africa. Clin Infect Dis 2003; 37:450-1.
10. Kuhn S, Gill MJ, Kain KC. Emergence of atovaquone-proguanil resistance during treatment of Plasmodium falciparum malaria acquired by a non-immune north American traveller to west Africa. Am J Trop Med Hyg 2005; 72:407-9.
11. Sutherland CJ, Laundy M, Price N, et al. Mutations in the Plasmodium falciparum cytochrome b gene are associated with delayed parasite recrudescence in malaria patients treated with atovaquone-proguanil. Malar J 2008; 7:240.
12. Rose GW, Suh KN, Kain KC, et al. Atovaquone-proguanil resistance in imported falciparum malaria in a young child. Pediatr Infect Dis J 2008; 27:567-9.
13. Wichmann O, Muehlen M, Gruss H, et al. Malarone treatment failure not associated with previously described mutations in the cytochrome b gene. Malar J 2004; 3:14.
14. Wurtz N, Pascual A, Marin-Jauffre A, et al. Early treatment failure during treatment of Plasmodium falciparum malaria with atovaquoneproguanil in the Republic of Ivory Coast. Malar J 2012; 11:1-4.
15. Musset L, Bouchaud O, Matheron S, et al. Clinical atovaquone-proguanil resistance of Plasmodium falciparum associated with cytochrome b codon 268 mutations. Microbes Infect 2006; 8:2599.
16. Wichmann O, Muehlberger N, Jelinek T, et al. Screening for mutations related to atovaquone/proguanil resistance in treatment failures and other imported isolates of Plasmodium falciparum in Europe. J Infect Dis 2004; 190:1541-6.
17. Muehlen M, Schreiber J, Ehrhardt S, et al. Short communication: prevalence of mutations associated with resistance to atovaquone and to the antifolate effect of proguanil in Plasmodium falciparum isolates from northern Ghana. Trop Med Int Health 2004; 9:361-3.
18. Pimentel S, Nogueira F, Benchimol C, et al. Detection of atovaquoneproguanil resistance conferring mutations in Plasmodium falciparum cytochrome b gene in Luanda, Angola. Malar J 2006; 5:30.
19. Berry A, Senescau A, Lelievre J, et al. Prevalence of Plasmodium falciparum cytochrome b gene mutations in isolates imported from Africa, and implications for atovaquone resistance. Trans R Soc Trop Med Hyg 2006; 100:986-8.
20. Parola P, Pradines B, Simon F, et al. Antimalarial drug susceptibility and point mutations associated with drug resistance in 248 Plasmodium falciparum isolates imported from Comoros to Marseille, France in 2004- 2006. Am J Trop Med Hyg 2007; 77:431-7.
21. Ekala MT, Khim N, Legrand E, et al. Sequence analysis of Plasmodium falciparum cytochrome b in multiple geographic sites. Malar J 2007; 6:164.
22. White N, Pongtavornpinyo W. The de novo selection of drug-resistant malaria parasites. Proc R Soc Lond B Biol Sci 2003; 270:545-54.
23. Chiodini P, Conlon C, Hutchinson D, et al. Evaluation of atovaquone in the treatment of patients with uncomplicated Plasmodium falciparum malaria. J Antimicrob Chemother 1995; 36:1073-8.
24. Looareesuwan S, Viravan C, Webster HK, et al. Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. Am J Trop Med Hyg 1996; 54:62-6.
25. Srivastava IK, Vaidya AB. A mechanism for the synergistic antimalarial action of atovaquone and proguanil. Antimicrob Agents Chemother 1999; 43:1334-9.
26. Collins WE, Sullivan JS, Hall P, et al. Adaptation of a multi-drug resistant strain of Plasmodium falciparum from Peru to Aotus lemurinus griseimembra, A. nancymaae, and A. vociferans monkeys. Am J Trop Med Hyg 2007; 77:261-5.
27. Akinyi S, Hayden T, Gamboa D, et al. Multiple genetic origins of histidine- rich protein 2 gene deletion in Plasmodium falciparum parasites from Peru. Sci Rep 2013; 3:2797.
28. Anderson T, Su X, Bockarie M, et al. Twelve microsatellite markers for characterization of Plasmodium falciparum from finger-prick blood samples. Parasitology 1999; 119:113-25.
29. McCollum AM, Mueller K, Villegas L, et al. Common origin and fixation of Plasmodium falciparum dhfr and dhps mutations associated with sulfadoxine-pyrimethamine resistance in a low-transmission area in South America. Antimicrob Agents Chemother 2007; 51: 2085-91.
30. Korsinczky M, Chen N, Kotecka B, et al. Mutations in Plasmodium falciparum cytochrome b that are associated with atovaquone resistance are located at a putative drug-binding site. Antimicrob Agents Chemother 2000; 44:2100-8.
31. Srivastava IK, Morrisey JM, Darrouzet E, et al. Resistance mutations reveal the atovaquone-binding domain of cytochrome b in malaria parasites. Mol Microbiol 1999; 33:704-11.
32. Kessl JJ, Ha KH, Merritt AK, et al. Cytochrome b mutations that modify the ubiquinol-binding pocket of the cytochrome bc1 complex and confer anti-malarial drug resistance in Saccharomyces cerevisiae. J Biol Chem 2005; 280:17142-8.
33. Durand R, Prendki V, Cailhol J, et al. Plasmodium falciparum malaria and atovaquone-proguanil treatment failure. Emerg Infect Dis 2008; 14:320.
34. Peters JM, Chen N, Gatton M, et al. Mutations in cytochrome b resulting in atovaquone resistance are associated with loss of fitness in Plasmodium falciparum. Antimicrob Agents Chemother 2002; 46:2435-41.
35. Fisher N, Majid RA, Antoine T, et al. Cytochrome b mutation Y268S conferring atovaquone resistance phenotype in malaria parasite results in reduced parasite bc1 catalytic turnover and protein expression. J Biol Chem 2012; 287:9731-41.
36. Happi CT, Gbotosho GO, Folarin OA, et al. Confirmation of emergence of mutations associated with atovaquone-proguanil resistance in unexposed Plasmodium falciparum isolates from Africa. Malar J 2006; 5:82.
37. Nair S, Williams JT, Brockman A, et al. A selective sweep driven by pyrimethamine treatment in Southeast Asian malaria parasites. Mol Biol Evol 2003; 20:1526-36.
38. Cortese JF, Caraballo A, Contreras CE, et al. Origin and dissemination of Plasmodium falciparum drug-resistance mutations in South America. J Infect Dis 2002; 186:999-1006.
39. Wongsrichanalai C, Pickard AL, Wernsdorfer WH, et al. Epidemiology of drug-resistant malaria. Lancet Infect Dis 2002; 2:209-18.
40. Naidoo I, Roper C. Mapping 'partially resistant','fully resistant', and 'super resistant'malaria. Trends Parasitol 2013; 29:505-15.
41. Schwöbel B, Alifrangis M, Salanti A, et al. Different mutation patterns of atovaquone resistance to Plasmodium falciparum in vitro and in vivo: rapid detection of codon 268 polymorphisms in the cytochrome b as potential in vivo resistance marker. Malar J 2003; 2:5.